decitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 1 inhibitor
pharma · Acute Myeloid Leukemia
Shanghai Tong Ren
Shanghai Tong Ren Hospital
Shanghai Tong Ren drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Shanghai Tong Ren pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Shanghai Tong Ren drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.